JRJ
PLX icon

Jeffrey R. Jay’s Protalix BioTherapeutics PLX Stock Holding History

Jeffrey R. Jay’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$1.96M Buy
+39,901
New +$2.12M 1.55% 18

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Jeffrey R. Jay's PLX Position: Q2 2013 in Review

Jeffrey R. Jay opened a new position in Protalix BioTherapeutics (PLX) in Q2 2013: 39,901 shares worth $1.96M. The stake represents 1.55% of the portfolio and ranks #18 among its holdings.

47 funds tracked by Wall St. Rank hold PLX as of Q2 2013.

  • Jeffrey R. Jay held 39,901 shares of Protalix BioTherapeutics worth $1.96M as of Q2 2013.
  • Protalix BioTherapeutics was a new Jeffrey R. Jay position in Q2 2013.
  • Protalix BioTherapeutics made up 1.55% of Jeffrey R. Jay's portfolio in Q2 2013, its #18 holding.
  • 47 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2013.

Based on Jeffrey R. Jay's 13F filing for Q2 2013, filed 14 Aug 2013.